A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

Retinitis pigmentosa (RP) is a major blinding eye disease, with a global prevalence of 1/9000-1/850. It's estimated that over 1.5 million Chinese people may have RP. Its typical clinical features are night blindness and progressive tunnel vision. In the disease's end stage, total loss of peripheral and central vision may occur, accounting for about 20% of all blinding causes. The main characteristic of RP is the progressive apoptosis of retinal photoreceptor cells, which leads to gradually worsening night blindness, concentric visual field constriction, and decreased visual acuity, among other visual function impairments.

The core of RP treatment is to slow down the progression of visual impairment and delay disease advancement. However, currently there are no effective clinical methods or recommended medications to control or slow RP's progression. In recent years, advanced therapies like gene therapy and stem cell treatments have been tried for RP but are still far from clinical application due to technical challenges. So, there's an urgent need for more accessible, widely applicable, and economical treatments.

RP has a complex and poorly understood etiology. Microglia, key resident macrophages in the central nervous system, when activated, can promote neurodegenerative diseases like RP. Suppressing this activation may slow disease progression. Minocycline, a tetracycline antibiotic with anti-inflammatory and immunomodulatory effects, can cross the blood - brain barrier and protect neurons by inhibiting microglial activation. It's been studied for treating neurodegenerative diseases such as Alzheimer's and Huntington's disease. A randomized controlled trial published in The New England Journal of Medicine in 2017 found that 6 months of 200mg daily minocycline for clinically isolated syndrome patients reduced their conversion rate to multiple sclerosis, showing minocycline's potential in neurodegenerative disease treatment. Safety studies indicate no antibiotic resistance after 36 months of 200mg daily minocycline used in geographic atrophy in age-related macular degeneration.

Our team completed a pilot study on minocycline for RP. The results showed that 12 months of 100mg daily minocycline improved RP patients' visual function with good tolerability.

Based on this, we plan a multicenter, randomized, double-blind, controlled clinical trial to get high - level evidence on minocycline's efficacy and safety for RP.

• The change of BCVA [Срок оценки: 12 months]
• The change of VF [Срок оценки: 12 months]
• The change of color vision [Срок оценки: 12 months]
• The change of microperimetry [Срок оценки: 12 months]
• The change of contrast sensitivity [Срок оценки: 12 months]
• The change of OCT [Срок оценки: 12 months]
• The change of NEI-VFQ-25 [Срок оценки: 12 months]
• The change of other ERG amplitude [Срок оценки: 12 months]